Literature DB >> 8258199

Biliary elimination and pharmacokinetics of vinorelbine in micropigs.

D Levêque1, M Merle-Melet, L Bresler, J P Didelot, J P Aymard, J Wihlm, F Jehl.   

Abstract

The biliary elimination and pharmacokinetics of vinorelbine (NVB) were investigated in five conscious micropigs provided with a double-terminal choledocal fistula allowing the collection and reinstillation of bile. After the i.v. administration of NVB (0.5 mg/kg), serum and bile samples were collected over a 48-h period. The concentrations of NVB were measured by high-performance liquid chromatography. The serum concentrations decreased rapidly from a maximal value of 208.6 ng/ml (SD, 111.7 ng/ml). The mean half-life was 10.9 h (SD, 8.6 h) and the mean AUC0-48 h was 292.8 ng ml-1 h (SD, 79.4 ng ml-1 h). The bile concentrations were high, amounting to 16.0 micrograms/ml (range, 5.4-27.7 micrograms/ml). The 0- to 48-h biliary excretion of unchanged NVB accounted for 25.8% (SD, 5.7%) of the injected dose, with 21.5% (SD, 4.0%) being eliminated during the 0- to 8-h period. Desacetyl-NVB was found in an inconstant manner and in very low amounts in bile samples. In addition, no glucuronide of NVB could be detected. Thus, in the micropig, biliary excretion represents an important route of elimination for NVB.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8258199     DOI: 10.1007/bf00685895

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  13 in total

1.  Pharmacokinetics and biliary elimination of temafloxacin in pigs.

Authors:  F Jehl; L Bresler; C Koechlin; M Merle-Melet; J P Didelot; J Hazebroucq
Journal:  J Antimicrob Chemother       Date:  1992-08       Impact factor: 5.790

2.  Navelbine in advanced ovarian epithelial cancer: a study of the French oncology centers.

Authors:  M J George; J F Heron; P Kerbrat; J Chauvergne; A Goupil; D Lebrun; J P Guastalla; M Namer; R Bugat; Y Ayme
Journal:  Semin Oncol       Date:  1989-04       Impact factor: 4.929

3.  Determination of navelbine and desacetylnavelbine in biological fluids by high-performance liquid chromatography.

Authors:  F Jehl; J Debs; C Herlin; E Quoix; C Gallion; H Monteil
Journal:  J Chromatogr       Date:  1990-01-26

4.  Pharmacokinetics and metabolism of vinblastine in humans.

Authors:  R J Owellen; C A Hartke; F O Hains
Journal:  Cancer Res       Date:  1977-08       Impact factor: 12.701

5.  Phase-II study of Navelbine in advanced breast cancer.

Authors:  L Canobbio; F Boccardo; G Pastorino; F Brema; C Martini; M Resasco; L Santi
Journal:  Semin Oncol       Date:  1989-04       Impact factor: 4.929

6.  Biliary excretion of vincristine.

Authors:  D V Jackson; M C Castle; R A Bender
Journal:  Clin Pharmacol Ther       Date:  1978-07       Impact factor: 6.875

7.  A new class of antitumor compounds: 5'-nor and 5',6'-seco derivatives of vinblastine-type alkaloids.

Authors:  P Mangeney; R Z Andriamialisoa; N Langlois; Y Langlois; P Potier
Journal:  J Org Chem       Date:  1979-10-01       Impact factor: 4.354

8.  Clinical pharmacokinetics of vinorelbine alone and combined with cisplatin.

Authors:  D Levêque; F Jehl; E Quoix; F Breillout
Journal:  J Clin Pharmacol       Date:  1992-12       Impact factor: 3.126

9.  Bile restitution procedures for studying bile secretion in fistulated pigs.

Authors:  C Juste; T Corring; Y Le Coz
Journal:  Lab Anim Sci       Date:  1983-04

10.  A phase II study of Navelbine (vinorelbine) in the treatment of non-small-cell lung cancer.

Authors:  A Depierre; E Lemarie; G Dabouis; G Garnier; P Jacoulet; J C Dalphin
Journal:  Am J Clin Oncol       Date:  1991-04       Impact factor: 2.339

View more
  3 in total

Review 1.  Clinical pharmacokinetics of vinorelbine.

Authors:  D Levêque; F Jehl
Journal:  Clin Pharmacokinet       Date:  1996-09       Impact factor: 6.447

2.  Pulmonary distribution of vinorelbine in patients with non-small-cell lung cancer.

Authors:  D Levêque; E Quoix; P Dumont; G Massard; J G Hentz; A Charloux; F Jehl
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

3.  A Pilot Study of Vinorelbine Safety and Pharmacokinetics in Patients with Varying Degrees of Liver Dysfunction.

Authors:  Jun Gong; May Cho; Rohan Gupta; Timothy W Synold; Paul Frankel; Christopher Ruel; Marwan Fakih; Vincent Chung; Dean Lim; Joseph Chao
Journal:  Oncologist       Date:  2019-02-01
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.